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Fixed drug eruptions are adverse 
cutaneous reactions to ingested drugs, 
characterized by the formation of 
solitary or multiple erythematous 
patches, plaques, bullae or erosions that 
reoccur at an identical skin site within 
hours of re ingestion of the offending 
drug. The objective of this study was to 
describe the epidemiology of Fixed drug 
eruptions with the identification of 
common causative drugs among patients 
at the dermatology clinic of an urban 
tertiary hospital in the South-south 
region ofNigeria. 
METHODS 
All consecutive patients with a diagnosis 
of fixed drug eruptions seen at the 
dermatology clinic between January 
2005 to January 2013 were included in 
the study. The diagnosis of fixed drug 
eruptions was made based on clinical 
findings of lesion (s) of the same form 
occurring twice or more at the same sites 
as a result of a readministration of a 
causative drug, and confirmation by a 
challenge test. 
RESULTS 
The diagnosis of fixed drug eruption was 
made in 99 out of5106 (1.93%) patients, 
with a slight female dominance. FDE 
affected all age groups, the youngest 
presented at 9months of age andthe 
oldest at 86years. Majority of patients 
(66. 7%) did not know the offending drug. 
The most implicated drugs were the 
sulphonamides (21.2%), followed by 
antibiotics made up of ampiclox, 
tetracycline and penicillin ( 4.04%) and 
Non steroidal anti inflammatory drugs 
(3.03%). The commonest site of 
presentation was the face (32%), 
especially the mucosa of the mouth, 
followed by generalized presentation 
(28%).The frequency of Lower limb 
presentation was (13%),followed by the 
upper limb (11%) and the trunk(7.1%). 
CONCLUSION 
Fixed drug eruptions are a cause for great 
concern to the patient. Consistent with 
some other studies sulphonamides, 
clotrimoxazole and fansidar were the 
most implicated drugs. 
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INTRODUCTION 
Fixed drug eruptions are a cause for great 
concern in our environment because of the 
cosmetic embarrassment it causes. Fixed drug 
eruptions are characterized by well 
circumscribed hyper pigmented macules or 
patches, erosions or bullae, that reoccur at 
sites of initial presentation for unknown 
reasons. The most characteristic presentation 
of fiXed drug eruption is a circumscribed lesion 
that heals with residual hyper pigmentation 
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and recur at the same anatomic site. Fixed 
drug eruption lesions initially appear when 
susceptible patients are sensitized to a 
particular drug. Such sensitization occurs 
more rapidly in patients intermittently 
receiving the causative drugs rather than 
those continuously receiving them. 
Careful history taking about drug intake and a 
prior history of recurrent lesions in the same 
sites are essential for the precise diagnosis of 
fixed drug eruptions2• The lesion usually flares 
within 30minutes to 8hours after drug intake; 
mean length of time from drug intake to the 
onset of symptoms is approximately two 
hours. Sensation of burning often precede the 
appearance of lesions2• Guin3 et al reported 
that FDE lesions appeared to migrate because 
some of the previously involved sites did not 
flare with each exposure whereas others 
flared. 
The causes of Fixed drug eruptions differ from 
one place to the other and from one time to the 
other depending on the availability of drugs, 
socioeconomic status, literacy and application 
and adherence of drug control measures4'5• The 
diagnosis and management of FDEs can be 
compounded by non-identification of the 
causative drug. In Nigeria this is a major 
challenge as there is a high patronage of 
patent medicine stores and other unregulated 
outlets that dispense drugs to patients without 
labels. 
There is a paucity of data on the epidemiology 
and pattern of fixed drug eruption in South-
South Nigeria. Such data peculiar to the 
environment will be useful in planning for 
FDE care as well as provide information for 
patient education. It is on this basis that the 
purpose of this study is to describe the 
epidemiology of fixed drug eruptions and give 
list of causative drugs and body sites affected 
in the South-South region ofNigeria. 
MATERMLSANDMETHODS 
All consecutive patients with a diagnosis of 
Fixed drug eruptions seen at the Dermatology 
clinic between January 2005 to January 2013, 
who gave informed consent were included in 
this retrospective study. 
Data was obtained from the medical records of 
patients diagnosed with fixed drug eruptions. 
Inclusion criteria included informed consent, 
patients above the age of five years and non 
pregnant and lactating patients. 
All institutional ethical protocol and 
guidelines were followed to protect patient's 
privacy and safety in the course of this 
retrospective study. Three Dermatology 
specialists validated the cases if they satisfied 
the following condition. Lesion(s) of the same 
form occurring twice or more at the same site 
as a result of re-administration of a causative 
drug. Confirmation by oral provocation tests 
was performed in an effort to confirm the 
history given by the patient. The patient's 
were given one tenth of the usual dose of the 
drug and it was considered positive. If 
previous FDE sites reactivated with marked 
erythema, burning and itching. This test was 
done with relative safety with a low risk of 
inducing systemic adverse reactions. 
RESULTS 
The diagnosis of FDE was made in 99 out of 
5106 a prevalence of (1.93%). There was a 
slight female preponderance with 54(54.54%) 
of females and 45 (45.45%) of males. The age 
range was from 9months to 86years with a 
mean of 43.5years. More patients were seen in 
the third decade 37(42.05%).Table 1 shows the 
age distribution of the subjects. 
Tablel: Showing age distribution of patients. 
Age distribution Number(%) 
0-10 2 (2.02%) 
11 -20 20 (2.02%) 
21-30 37 (42.05%) 
31-40 12 (12.1%) 
41-50 8 (8.08%) 
51-60 8 (8.08%) 
61-70 7 (7.07%) 
71-80 3 (3.03%) 
81-90 2 (2.02%) 
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Out of the 99 patients with FDEs 33 (33.33%) commonest with 13 (39.4%) patients affected, 
could identify the implicatingdrugs and this followed by generalized presentation with 
was confirmed by oral provocation tests. The 9(27.3%). 
offending drug could not be identified in66 
(66.67%) of patients. 
Table 2, shows the frequency of drug 
involvement in FDEs using the oral 
provocation test. Oral provocation tests 
indicated that trimethoprim and 
sulfamethoxazole (co-trimoxazole) was the 
cause of FDE in 16(48%) of patients followed 
by fansidar 4 ( 12.12% ),penicillin 2( 6.06% ). 
The following had 1(3.03%) respectively: 
griseofulvin, metakelfin, piroxicam, naloxone, 
Ibuprofen, buscopan, ampiclox, tetracycline 
and quinine. Two patients gave a history of 
taking local herbs , this could not be verified by 
oral provocation tests. 
Table 2: Showing list of implicated drugs with 
percentages. 
Name of 
drug Number Percentages(%) 
Co-trim 
oxazole 16 48 
Fansidar 4 12.12 
Penicillin 2 6.06 
local herbs 2 6.06 
Griseofulvin 1 3.03 
metakelfin 1 3.03 
Piroxicam 1 3.03 
Naloxone 1 3.03 
Ibuprofen 1 3.03 
Buscopan 1 3.03 
Ampiclox 1 3.03 
Tetracycline 1 3.03 
Quinine 1 3.03 
Fixed drug eruptions most often involved the 
face and the lips in co-trimoxazole, with 
16(37.5%) patients affected, and a male 
preponderance of 9(56.25%). The only case of 
genital affectation was in a female. Fansidar 
had 2 (50%) of patients with face and lip 
involvement and a male preponderance of 
3(75%). The facial presentation was the 
Two thirds of the patients with FDEs from 
non-steroidal anti-inflammatory drugs 
(naloxone and ibuprofen) showed limb 
presentations. Antibiotics (Ampicloxand 
tetracycline)had facial manifestations while 
the presentation with penicillin induced FDE 
was generalized. The distribution of the body 
sites involved in FDEs is shown in table 3. 
Table 3: Showing drugs with sites of body 
involvement. 
Drug Male Female Face Genital Trunk Limbs Generalized 
Co-
trimoxazole 9 7 6 1 2 3 4 
Fansidar 3 1 2 0 0 0 2 
Penicillin 0 2 0 0 0 0 2 
U>calherbs 1 1 1 0 0 0 1 
Griseofulvin 0 1 0 0 0 1 0 
Me take !.fin 0 1 0 0 1 0 0 
Piroxicam 0 1 1 0 0 0 0 
Naloxone 1 0 0 0 0 1 0 
Ibuprofen 0 1 0 0 0 1 0 
Buscopan 0 1 0 0 1 0 0 
Ampiclox 1 0 1 0 0 0 0 
Tetracycline 0 1 1 0 0 0 0 
Quinine 1 0 1 0 0 0 0 
'Ibtal 16 17 13 1 4 6 9 
DISCUSSION 
Fixed drug eruption is a cause of great concern 
to our patients because of the obvious residual 
hyper pigmentation it manifests with. It 
affects all ages 6 with a wide range from 
9monthsto 86years reported in this study. 
More patients were in their third decade of life. 
This is coroborated by other studies that had 
patients between the ages of 20 to 40 years7'8 • 
No specific explanation can be given for this 
age distribution ofFDE reported in this study. 
More females were affected in this study 
54(54.54%), with a ratio of 1.2:1, comparable 
with the study from Pakistan9 with a men to 
women ratio of 1:1.1, this is contrasted by the 
studies of Schgal6 and Nnoruka1 with male 
preponderance.9The female preponderance in 
this study does not appear to be significant. 
The overall prevalence of FDE in this study 
was 1.93%. The prevalence of fixed drug 
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eruption in a study in lbadan was 2.2%10, while 
a study in Enugu reported a prevalence of 
0.5%1• The prevalence of FDEs in studies 
outside Nigeria, in Pakistan documented a 
prevalence of0.7%9 • Fixed drug eruptions in a 
study in Cameroun1\ caused 60.7% of reported 
adverse cutaneous drug reactions. The results 
of the study in lbadan10 is comparable to that 
of our study, while that of Enugu1 and 
Pakistan9 are lower (0.7%). The variations in 
this prevalence of the various studies may be 
due to better adherence and application of 
drug control measures and the pattern of drug 
prescriptions in these settings. It is known 
that some cases of recurrent exacerbations of 
FDE lesions without significant history of 
drug intake might be attributable to 
nonspecific exogenous factors. Non medical 
factors such as food and ultraviolet 
irradiation, have also been reported to 
precipitate exacerbations of FDE lesions12'13'14• 
This could explain the large number of 
patients with no history of drug intake in this 
study. In addition that high utilization of 
patent medicine stores in this region that 
dispense drugs to patients without a 
prescription and labelling also results in the 
inability of the patients to identify the 
causative drugs they used by name. 
The finding of patients without knowledge of 
the causative drug in this study is similar to 
that of a study in Korea15 with 134 patients 
with FDE, that reported only 38(28.4%) with a 
clear documentation of causative drugs, 
comparable to the 33.33% reported in this 
study. This scenario poses a challenge for the 
confirmation of FDE diagnosis as the Oral 
provocation tests which is the most reliable 
way of testing for FDE16 is impossible to 
implement without a knowledge of the 
offending drug. 
Co-trimoxazole accounted for 48.5% of fixed 
drug eruptions in this study and induced 
lesions mainly on the face and lips. This is 
consistent with the outcome of other studies 
that found co-trimoxazoleto be the most 
implicated drug6'17'18'19• Nnoruka, et allaslo 
reported that anti-malarials containing 
sulfadoxine and pyrimethamine were the 
commonest causes of FDEs in a study in 
Enugu, with the mucosa of the lips as the 
commonest site. The outcome of their study1is 
in line with our findings from this study and 
highlights the importance of sulfonamides as 
major cause of FDEs and other forms of 
adverse drug reactions. 
The findings in our study of cotrimoxazole as 
the most frequent cause ofFDE, is contrasted 
by Olumide20 who found pyrazolone analgesics 
to be the most implicated. This difference in 
pattern may be due to the fact that at the time 
of this study pyrazoloneanalgesics are no 
longer commonly used. The trend of NSAIDS 
and analgesics as a predominant cause of 
FDEs is also reported by a Jung et al, in Korea 
who found Non-steroidal anti-
inflammatorydrugs and acetaminophen to be 
the mostimplicated15 in FDEs accounting for 
71% of patients with accounted drug history. 
The large proportion of subjects (72.6%) in this 
study who had no knowledge of the offending 
drug in this study may be responsible for this 
outcome. As NSAIDs and acetaminophen may 
be sold over the counter and most people have 
a good knowledge of these drugs. 
CONCLUSION 
Sulphonamides are the commonest cause of 
FDE in this study. The commonest site of 
presentation ofFDE lesions was the face, with 
a majority of patients not knowing the 
causative drug. It is recommended that the 
strict application and adherence of drug 
control measures be implemented to reduce 
the number of FDEs patients who cannot 
identify the causative drug. Better regulation 
of patent medicine stores and improved 
pharmacovigilance process are required to 
improve our knowledge and management of 
FDEs. 
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